IntelGenx Files Provisional U.S. Patent Application for Advanced Oral Film Formulation Improving Cannabinoid Onset of Action

Rhea-AI Summary

IntelGenx Corp. (TSX:IGX) has filed a new provisional patent application with the USPTO for 'Advanced Oral Film Formulations.' This patent focuses on cannabinoid administration for faster onset, supporting the development of non-combustible cannabis products. The application allows for the inclusion of THC and CBD in buccal and sublingual films, optimizing the effects. Dr. Horst G. Zerbe noted this filing enhances their intellectual property portfolio. IntelGenx is committed to expanding this technology internationally as the patent progresses.

Positive

• The new patent application could significantly enhance the company's intellectual property portfolio.
• The formulation aims to optimize the onset of action for cannabinoids, potentially increasing product effectiveness.
• The technology allows for the integration of multiple cannabinoids, broadening product offerings.

Negative

• None.

SAINT LAURENT, Quebec, Nov. 02, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical films, today announced it has filed a new provisional patent application with the United States Patent and Trademark Office (“USPTO”) entitled “Advanced Oral Film Formulations” (the "Patent Application"). The Patent Application contains new inventive claims with respect to administering cannabinoids for quicker onset of action, and further demonstrates the progress that the Company is making toward developing non-combustible product alternatives that can have a meaningful impact on both the medical- and recreational-use cannabis markets.

The Patent Application covers a newly-developed platform that enables the incorporation of lipophilic active ingredients and cannabinoids such as THC, in buccal and sublingual oral film formulations of cannabis-infused products, while optimizing onset of action. The technology may also be used when more than one ingredients, such as THC and CBD, are applied in a single film product.

“This new filing adds to the global intellectual property estate that we are building for VersaFilm^®,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx. “We also anticipate making filings protecting this newly-developed platform in several additional international jurisdictions as the Patent Application progresses through the USPTO process.”

About IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx’s superior film technologies, including VersaFilm^®, DisinteQ^™, VetaFilm^™ and transdermal VevaDerm^™, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.

Forward-Looking Information and Statements

This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Source: IntelGenx Technologies Corp.

For IntelGenx:

Stephen Kilmer
Investor Relations
(647) 872-4849
stephen@kilmerlucas.com

Or

Andre Godin, CPA, CA
President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com 

FAQ

What is the significance of IntelGenx's new patent application filed on Nov 2, 2022?

The new patent application enhances IntelGenx's intellectual property by focusing on faster cannabinoid administration through advanced oral film formulations.

How does IntelGenx's patent application impact cannabinoid delivery?

The application enables the incorporation of THC and CBD in oral film formulations, optimizing the onset of action for cannabis products.

What are the potential markets for IntelGenx's new oral film formulations?

The formulations target both medical and recreational cannabis markets, offering non-combustible alternatives.

What are the future plans for the new patent application by IntelGenx?

IntelGenx plans to file for protection of the new platform in several international jurisdictions as the application progresses.